Abstract
Abstract Background: Several genomic assays are available to profile early breast cancer (eBC) that according to current evidence, can provide reliable information on the risk of recurrence. However, little is known regarding their current clinical use and the perception of their utility among European breast cancer (BC) specialists. The PROCURE project aims to develop a consensus on the utility of BC multigene signatures (BCMS) in treatment decision making for different BC patient profiles. Methods: A Scientific Committee of 8 experts in BC from 8 European countries developed a Delphi questionnaire that was administered in two waves to experienced clinicians across Europe with expertise in the use of BCMS. The questionnaire included 5 sections: 1) Participants’ profile and experience with BCMS. 2) Current clinical practice in eBC and use of BCMS. 3) Participants’ opinion on the utility of the BCMS in eBC according to patient profiles. 4) Agreement with a set of recommendations on the use of BCMS in clinical practice. 5) Identification of unmet needs and future applications of BCMS. 70% agreement was used to determine consensus on a topic. Results: 163 BC experts were invited to answer anonymously the online Delphi questionnaire. At wave 2 closure (1st of June 2021) 133 panelists from 11 European countries (grouped in 5 regions) completed both rounds of the survey. Panelists were 48.8 years old (± 9.5). 86.5% of them worked in a teaching hospital, 72.2% were medical oncologists and 12.0% pathologists, the distribution of the specialities of the participants differed by region. The mean number of patients seen, treated or diagnosed on a weekly basis was 36.4 with statistical differences among regions and specialities. The ratio of eBC on BC patients was 63.5%, similar between regions but showed statistical differences among specialities. 93.2% of the panelists used BCMS routinely or in selected patients, with statistical differences among regions, and 73.4% had more than 5 years of experience using BCMS, however the experience of participants varies by regions and specialities. After the 2nd wave, experts panelists in BC management reached a consensus on 50% (35/70) of the items asked on clinical utility, recommendations and future applications of BCMS. Conclusions: European panelists that participated in the PROCURE study showed an extensive experience in the management of BC patients and on the use of BCMS. Detailed results from the 2nd wave will be presented during the 2021 SABCS meeting to engage larger discussion with symposium participants about the agreement or disagreement reached on the main topics. Citation Format: Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frédérique Penault-Llorca, Aleix Prat. Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-06-08.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
